Clinical Research Directory
Browse clinical research sites, groups, and studies.
Comparison of Intravenous Labetalol and Intravenous Hydralazine in Severe Preeclampsia
Sponsor: Muhammad Aamir Latif
Summary
Due to limited data regarding preeclampsia from the local population, the debate is still ongoing in the study setting. Hence, the current study was planned to compare the efficacy of labetalol and hydralazine for the treatment of hypertension in patients with severe preeclampsia.
Official title: Comparison of the Efficacy of Intravenous Labetalol and Intravenous Hydralazine for the Treatment of Hypertension in Patients With Severe Preeclampsia.
Key Details
Gender
FEMALE
Age Range
20 Years - 35 Years
Study Type
INTERVENTIONAL
Enrollment
132
Start Date
2024-05-01
Completion Date
2024-10-31
Last Updated
2026-05-07
Healthy Volunteers
No
Conditions
Interventions
Labetalol
Patients were given a 20 mg bolus dose of labetalol in 2 minutes, and blood pressure was checked after 20 minutes; if not effective, then a 40 mg dose of labetalol was given. If still no effect was seen, then 80 mg was given every 20 minutes up to a maximum dose of 300 mg, and every time blood pressure was checked after 20 minutes.
Hydralazine
Patients were given intravenous hydralazine, 5 mg in a bolus dose, then repeated every 20 minutes as needed up to five doses; a maximum of 25 mg was given.
Locations (1)
Sadiq Abbasi Hospital
Bahawalpur, Punjab Province, Pakistan